

Time to Initiation of Antiretroviral Therapy between 4 Weeks and 12 Weeks of Tuberculosis Treatment in HIV-1 Infected Patients: Results from the TIME Study

Weerawat Manosuthi¹,
Aroon Lueangniyomkul¹,
Wiroj Mankatitham¹,
Supeda Thongyen¹,
Sirirat Likanonsakul¹,
Pawita Suwanvattana¹,
Unchana Thawornwan¹,
Busakorn Suntisuklappon¹,
Samruay Nilkamhang¹,
Somnuek Sungkanuparph², for the TIME Study Team

Background: Optimal timing for initiation of antiretroviral therapy (ART) among HIV-1 infected patients with tuberculosis (TB) is limited in the setting of early ART at CD4 count of < 350 cells/mm³ in the middle income countries.

Methods: Thai HIV/TB co-infected patients who had CD4 count of < 350 cells/mm³ and diagnosed TB were randomized to initiate a once daily regimen of tenofovir/lamivudine/efavirenz at 4 weeks (group A) versus 12 weeks (group B) of TB treatment between 2009-2011. The primary endpoints were all-cause mortality and hospitalization according to an intent-to-treat analysis.

Results: Of 156 patients, 79 were in group A and 77 patients were in group B. Overall mean \pm SD age was 38 \pm 9 years; median (IQR) CD4 was 43 (47-106) cells/mm³; and median (IQR) HIV-1 RNA was 5.8 (5.4-6.3) log copies/mL. Eighty-three (53%) patients were

diagnosed extra-pulmonary or disseminated TB. Eleven (7%) mortalities occurred in a totaling of 137 patient-years of follow-up. Seven percent (6/79, 8.76 per 100 patient-years) mortalities were in group A and 6% (5/77, 7.25 per 100 person-years) mortalities were in group B (OR=0.845, 95% CI=0.247-2.893, P > 0.99). The same trends were found in the subgroup of patients with baseline CD4 count < 100 vs 100 cells/mm³ (9% vs 11%, OR=1.239, 95% CI=0.338-4.542, P=0.753) and < 50 vs. \geq 50 cells/mm³ (9% vs. 13%, OR=1.596, 95% CI=0.396-6.397, P=0.725). Twenty-eight (35%) patients in group A and 25 (32%) patients in group B were hospitalized (OR=1.142, 95% CI=0.588-2.217, P=0.737). Grade 2-4 adverse events related to ART and TB treatment were 39% (31/79) in group A and 34% (26/77) in group B (OR=1.267, 95% CI=0.659-2.435, P=0.509). In multivariate analysis adjusting for timing to initiating ART, 'low albumin' (OR=3.717,

¹Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi 11000, Thailand.

²Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 14000, Thailand.

Received for publication: September 12, 2011.

95% CI=1.529-9.009, P=0.004) and 'low baseline CD4 count' (OR=1.014, 95% CI=0.999-1.029, P=0.061) were the independent predictors of all-cause mortality. Immune reconstitution inflammatory syndrome was more frequent in group A with an incidence of 8.86 vs. 5.02 per 100 person-months in group B over the first 6 months of ART (P=0.08).

Conclusions: In this study which conducted in a middle income country with early ART at CD4 count of <350 cells/mm³, survival advantage associated with very early initiating ART in HIV-infected patients with active TB was not found in any CD4 stratum. However, patients with low albumin and low baseline CD4 count were associated with higher risk of death.